AU Patent

AU2012288632A1 — New (trimethoxyphenylamino)pyrimidinyl formulations

Assigned to Rigel Pharmaceuticals Inc · Expires 2014-02-20 · 12y expired

What this patent protects

There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory

USPTO Abstract

There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory

Drugs covered by this patent

fostamatinib-disodium (FOSTAMATINIB DISODIUM)

Patent Metadata

Patent number: AU2012288632A1
Jurisdiction: AU
Classification: —
Expires: 2014-02-20
Drug substance claim: No
Drug product claim: No
Assignee: Rigel Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.